top of page
The Professional Network for Healthcare Experts
FDA approves GSK Hibsago bepirovirsen as first antisense treatment for chronic hepatitis B
The FDA has approved GSK's Hibsago as the first antisense oligonucleotide treatment for chronic hepatitis B, offering eligible patients a new approach to sustained viral control.
nuaxia
2 days ago2 min read
FDA grants accelerated approval to GSK Jemperli for MSI-H or dMMR locally advanced rectal cancer
The FDA has granted accelerated approval to GSK's Jemperli for previously untreated MSI-H or dMMR locally advanced rectal cancer, introducing a potentially organ-preserving immunotherapy approach.
nuaxia
3 days ago2 min read
GSK expands AI drug discovery collaboration with Chai Discovery following successful laboratory evaluation
GSK has expanded its collaboration with Chai Discovery to apply AI-powered protein modelling and molecular design tools across pharmaceutical drug discovery following successful laboratory validation.
nuaxia
Oct 142 min read
GSK acquires Chimagen trispecific T-cell engager programme in deal worth up to $750m
GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.
nuaxia
Sep 162 min read
GSK licenses HUTCHMED cancer therapy HMPL-A830 in deal worth up to $1.295bn
The agreement gives GSK worldwide rights outside Greater China to develop and commercialise HUTCHMED's first-in-class KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830.
nuaxia
Sep 42 min read
GSK’s $10.6bn Nuvalent Deal Marks a Shift Back to Late-Stage Oncology Scale Plays
GSK has agreed to acquire Nuvalent in a $10.6bn all-cash transaction, bringing a trio of late-stage lung cancer assets into its oncology portfolio and marking one of the company’s largest strategic moves in over a decade.
nuaxia
Jun 103 min read
bottom of page